ALK-Abelló Balance Sheet Health
Financial Health criteria checks 6/6
ALK-Abelló has a total shareholder equity of DKK6.2B and total debt of DKK172.0M, which brings its debt-to-equity ratio to 2.8%. Its total assets and total liabilities are DKK8.5B and DKK2.3B respectively. ALK-Abelló's EBIT is DKK1.5B making its interest coverage ratio 739. It has cash and short-term investments of DKK666.0M.
Key information
2.79%
Debt to equity ratio
DKK 172.00m
Debt
| Interest coverage ratio | 739x |
| Cash | DKK 666.00m |
| Equity | DKK 6.17b |
| Total liabilities | DKK 2.30b |
| Total assets | DKK 8.47b |
Recent financial health updates
ALK-Abelló (CPH:ALK B) Seems To Use Debt Quite Sensibly
Jan 23
Does ALK-Abelló (CPH:ALK B) Have A Healthy Balance Sheet?
Oct 11ALK-Abelló (CPH:ALK B) Seems To Use Debt Quite Sensibly
Jun 17Here's Why ALK-Abelló (CPH:ALK B) Can Manage Its Debt Responsibly
Mar 12Recent updates
Pediatric Allergy Tablets And Food Programs Will Drive A Long Runway Of Opportunity
Catalysts About ALK-Abelló ALK Abelló develops and commercialises allergy immunotherapy tablets, injectable and drop therapies, along with anaphylaxis treatments such as Jext and neffy. What are the underlying business or industry changes driving this perspective?ALK-Abelló (CPH:ALK B) Seems To Use Debt Quite Sensibly
Jan 23Investors Appear Satisfied With ALK-Abelló A/S' (CPH:ALK B) Prospects
Dec 08ALK-Abelló A/S (CPH:ALK B) Just Reported And Analysts Have Been Lifting Their Price Targets
Nov 15Does ALK-Abelló (CPH:ALK B) Have A Healthy Balance Sheet?
Oct 11ALK-Abelló A/S' (CPH:ALK B) Popularity With Investors Is Clear
Jul 23ALK-Abelló (CPH:ALK B) Seems To Use Debt Quite Sensibly
Jun 17Is There An Opportunity With ALK-Abelló A/S' (CPH:ALK B) 24% Undervaluation?
May 04Here's Why ALK-Abelló (CPH:ALK B) Has Caught The Eye Of Investors
Apr 16Here's Why ALK-Abelló (CPH:ALK B) Can Manage Its Debt Responsibly
Mar 12Earnings Update: ALK-Abelló A/S (CPH:ALK B) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Feb 22
Allergy+ Strategy And Neffy Nasal Spray Will Ignite Revenue Growth And Boost Earnings
The Allergy+ strategy and neffy nasal spray deal are expected to create new revenue streams and drive growth from 2025 onward.Financial Position Analysis
Short Term Liabilities: ALK B's short term assets (DKK3.6B) exceed its short term liabilities (DKK1.4B).
Long Term Liabilities: ALK B's short term assets (DKK3.6B) exceed its long term liabilities (DKK878.0M).
Debt to Equity History and Analysis
Debt Level: ALK B has more cash than its total debt.
Reducing Debt: ALK B's debt to equity ratio has reduced from 22.1% to 2.8% over the past 5 years.
Debt Coverage: ALK B's debt is well covered by operating cash flow (900%).
Interest Coverage: ALK B's interest payments on its debt are well covered by EBIT (739x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/09 21:50 |
| End of Day Share Price | 2026/02/09 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ALK-Abelló A/S is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Jesper Ilsoe | Carnegie Investment Bank AB |
| Jesper Ilsøe | DNB Carnegie |